

Appl. No. : 09/625,049
Filed : July 24, 2000

Please cancel page 8/14 of original Figure 7A and substitute therefor attached Substitute page 8/14 which identifies the amino acid sequences in Figure 7A as follows: L4 is SEQ ID NO:41, H2 is SEQ ID NO:38, L5 is SEQ ID NO:42, and H2 is SEQ ID NO:38.

Please cancel page 9/14 of original Figure 7B and substitute therefor attached Substitute page 9/14 which identifies the amino acid sequences in Figure 7B as follows: L8 is SEQ ID NO:40, L4 is SEQ ID NO:41, L5 is SEQ ID NO:42, L6 is SEQ ID NO:43, L7 is SEQ ID NO:44 and H2 is SEQ ID NO:38.

Please cancel page 10/14 of original Figure 7C and substitute therefor attached Substitute page 10/14 which identifies the amino acid sequences in Figure 7C as follows: L8 is SEQ ID NO:40, L4 is SEQ ID NO:41, L5 is SEQ ID NO:42, L6 is SEQ ID NO:43, L7 is SEQ ID NO:44, and H1 is SEQ ID NO:48.

Please cancel page 12/14 of original Figure 9A and substitute therefor attached Substitute page 12/14 which identifies the amino acid sequences in Figure 9A as follows: H2 is SEQ ID NO:38 and L2 is SEQ ID NO:39.

Please cancel page 13/14 of original Figures 9B and 9C and substitute therefore attached Substitute page 13/14 which identifies the amino acid sequences in Figure 9B as follows: L4 is SEQ ID NO:41, L5 is SEQ ID NO:42, and H2 is SEQ ID NO:38 and which identifies the amino acid sequences in Figure 9C as follows: L6 is SEQ ID NO:43, H6 is SEQ ID NO:45 (also H62), L7 is SEQ ID NO:44, and H7 is SEQ ID NO:47.

Please cancel page 14/14 of original Figure 10 and substitute therefor attached Substitute page 14/14 which identifies the amino acid sequences in Figure 10 as follows: H62 is SEQ ID NO:45, H61 is SEQ ID NO:46, H62 is SEQ ID NO:45, and L4 is SEQ ID NO:41.

REMARKS

Amendments to the drawings are made to refer to the sequence identification numbers given to nucleotide and amino acid sequences disclosed in the specification. These amendments are supported by the specification, in particular the Sequence Listing. No new matter has been added.

Response to Restriction Requirement

The Examiner divided the claims into the following four groups:

Group I: Claims 43-50 and 61-66, drawn to a multipurpose heterodimeric antibody derivative

Group II: Claim 51, drawn to a method of treating cancer, infections, autoimmune diseases or thrombosis